Metropolis Healthcare Achieves Double-Digit Revenue Growth in Q4FY25 Despite Industry Challenges

Metropolis Healthcare Ltd, in accordance with SEBI regulations, has provided a business update for Q4FY25. The healthcare industry faced weaker performance, but the company managed to achieve double-digit revenue growth. The acute testing segment experienced a slowdown due to weather conditions and lower elective procedures in major metropolitan hospitals. However, the wellness segment showed robust growth. Revenues grew by approx. 10% on a Y-o-Y basis, driven by patient volume growth, test volume growth, and change in product mix. B2C revenues grew at approx. 14% on a Y-o-Y basis. Operational EBITDA grew marginally lower due to higher material costs and reduced revenue growth. The company is debt free with cash reserves of approx. INR 112 crores. The financial results are subject to review by Auditors.